An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Phase of Trial: Phase III
Latest Information Update: 16 May 2019
Price : $35 *
At a glance
- Drugs Levoketoconazole (Primary)
- Indications Cushing syndrome
- Focus Registrational; Therapeutic Use
- Acronyms SONICS
- Sponsors Strongbridge Biopharma
- 25 Mar 2019 According to a Strongbridge Biopharma media release, secondary endpoint results were presented at the 16th Annual International Pituitary Congress (IPC).
- 25 Mar 2019 Results presented in a Strongbridge Biopharma media release.
- 18 Mar 2019 Results of subgroup analysis of Cushings syndrome (CS) patients with diabetes mellitus (DM), were presented at the 101st Annual Meeting of the Endocrine Society (ENDO 2019).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History